ESMO IMMUNO-ONCOLOGY CONGRESS: SITC PRIMER AND COLLABORATIVE SESSION

Program Information:
For the fourth year in a row, ESMO has collaborated with SITC to develop an ESMO IO Primmer and Collaborative Session at the 2022 ESMO Immuno-Oncology Congress. This global meeting will offer an advanced educational programme and the latest scientific developments in the promising field of immunotherapy. From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.


Learning Objectives 

• Update your knowledge on the fast-developing field of cancer immunotherapy
• Review state-of-the-art in novel diagnostics, biomarkers and therapeutic strategies in immune-oncology
• Understand recent developments on immune modulation, including tumour microenvironment, immunometabolism, epigenetics or microbiome
• Update your knowledge on novel immune-oncology strategies including immune-cells therapies, multi-specific antibodies, oncolytic virus or cancer vaccines
• Be informed on emerging evidence and research on immunotherapies in combination with other anti-cancer targeted therapies

Primer and Collaborative Session Co-chairs: 

• Tullia Bruno, PhD – University of Pittsburgh
• Avery Posey, PhD – University of Pennsylvania Perelman School of Medicine

Visit the ESMO IO 2022 Annual Congress webpage to learn more about this event and register to attend. If you are interested in viewing the meeting programme you can do so here.

More information